Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab in ulcerative colitis.

Faten N Aberra1, Gary R Lichtenstein

  • 1Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.

Gastroenterology Clinics of North America
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic Approaches for Disorders of Gut-Brain Interaction Other Than Medication.

Gastroenterology & hepatology·2026
Same author

Update on the Management of Pregnant Patients With Inflammatory Bowel Disease.

Gastroenterology & hepatology·2026
Same author

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.

The American journal of gastroenterology·2026
Same author

Nutritional Management of Adult Patients Who Have Crohn's Disease.

Gastroenterology & hepatology·2026
Same author

The Evolving Concept of a Therapeutic Window of Opportunity for Crohn's Disease.

Gastroenterology & hepatology·2026
Same author

Letter to the Editor.

The American journal of gastroenterology·2026

Infliximab effectively treats moderate-to-severe ulcerative colitis (UC) when other therapies fail. Further research is needed to optimize infliximab use and explore other anti-TNF agents for improved outcomes.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Current treatments include immunomodulators, corticosteroids, and mesalamine.
  • Infliximab is an anti-tumor necrosis factor (anti-TNF) agent used for UC.

Purpose of the Study:

  • To evaluate the efficacy of infliximab in moderate-to-severe UC.
  • To determine the role of infliximab in patients with inadequate response or intolerance to other therapies.
  • To identify future research directions for anti-TNF agents in UC.

Main Methods:

  • Review of existing clinical data and treatment guidelines for infliximab in UC.
  • Analysis of the risk-benefit profile of infliximab compared to conventional therapies.

Related Experiment Videos

  • Identification of unanswered questions regarding infliximab and other anti-TNF agents.

    • Main Results:

    • Infliximab demonstrates effectiveness in treating moderate-to-severe UC.
    • It is recommended for patients unresponsive or intolerant to other treatments.
    • The combination of infliximab with immunomodulators requires further investigation.

    Conclusions:

    • Infliximab is a valuable therapeutic option for moderate-to-severe UC.
    • Additional trials are necessary to optimize infliximab's risk-benefit ratio, particularly in combination with immunomodulators.
    • Further research into other anti-TNF agents and administration strategies is warranted to enhance efficacy and reduce side effects.